<DOC>
	<DOCNO>NCT01535040</DOCNO>
	<brief_summary>RATIONALE : Memantine hydrochloride may help people stop smoke decrease symptom nicotine withdrawal . PURPOSE : This randomize , pilot phase II trial study effective memantine hydrochloride work compare placebo help cancer survivor stop smoking .</brief_summary>
	<brief_title>Memantine Hydrochloride Helping Cancer Survivors Stop Smoking</brief_title>
	<detailed_description>OBJECTIVES : Primary - Estimate participation , accrual , adherence , retention cancer survivor smoke randomized receive memantine ( memantine hydrochloride ) ( 10 mg twice daily ) match placebo 12 week . - Estimate self-reported abstinence rate patient randomized memantine match placebo 12 week obtain preliminary estimate treatment effect ( difference abstinence rate two group ) . Secondary - Nicotine addiction assess use Wisconsin Inventory Smoking Dependent Motives . - Nicotine withdrawal measure Wisconsin Smoking Withdrawal Scale . - Quality life measure SF12 questionnaire . - Toxicities assess use Common Terminology Criteria Adverse Events ( CTCAE ) version 4 . OUTLINE : This randomize , placebo-controlled , pilot study . Participants stratify accord gender ( male v female ) . Participants randomize 1 2 treatment arm . - Arm I : Participants receive memantine hydrochloride orally ( PO ) twice daily ( BID ) day 1-81 absence unacceptable toxicity . - Arm II : Participants receive placebo PO BID day 1-81 absence unacceptable toxicity . Participants complete Behavioral Risk Factor Surveillance Survey ( BRFSS ) , Self-reported Tobacco Abstinence , Wisconsin Inventory Smoking Dependent Motives , Wisconsin Smoking Withdrawal Scale , SF-12 quality-of-life questionnaire , Fagerstrom Nicotine Tolerance Scale baseline every 2 week 12 week study . Participants also undergo urine sample collection week 4 , 8 , 12 cotinine test use NicAlert test .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Tobacco Use Disorder</mesh_term>
	<mesh_term>Memantine</mesh_term>
	<criteria>INCLUSION CRITERIA : Survivors nonmetastatic breast , prostate , colorectal cancer , stage I/II nonsmall cell lung cancer Age ≥ 18 Smoked 100 tobacco cigarette lifetime time first interview , smoke 10 cigarette per day day past month Eastern Cooperative Oncology Group ( ECOG ) performance status 01 ( Karnofsky ≥ 70 % ) Ability understand willingness sign write informed consent document Agrees adhere study protocol attend require clinic visit Negative serum pregnancy test within 10 day prior registration woman childbearing potential ; woman childbearing potential must agree use adequate contraception ( hormonal barrier method birth control ; abstinence ) prior study entry duration study participation Women currently breastfeed eligible study Use chew tobacco , pipe tobacco , snuff , noncigarette tobacco product allow No patient clinically significant uncontrolled medical condition ( e.g. , unstable angina , myocardial infarction , transient ischemic attack [ TIA ] , cerebral vascular accident [ CVA ] ) within past 3 month Creatinine ≥ 2 time upper limit normal ( ULN ) last six month Serum glutamic oxaloacetic transaminase ( SGOT ) /serum glutamic pyruvate transaminase ( SGPT ) ≥ 3 time ULN last six month Current uncontrolled hypertension ≥ 160/90 mm Hg Excessive alcohol abuse define 5 drink per day men 4 drink per day woman Major medical psychiatric illness , opinion investigator , would prevent completion treatment would interfere followup History allergic reaction attribute memantine PRIOR CONCURRENT THERAPY : Six month post definitive treatment ( except ongoing hormonal targeted therapy ) Patients currently must take Nicotine Replacement Therapy ( NRT ) agree start NRT duration study Patients currently take antidepressant antianxiety medication must stable dose 4 week prior registration Patients currently receive follow medication eligible : anticonvulsant agent ( e.g. , phenytoin , carbamazepine , gabapentin , etc . ) ; antiparkinsonian agent ( e.g. , Levo Dopa , ropinirole ) ; neuroleptic agent ( e.g. , risperidone , quetiapine ) ; carbonic anhydrase inhibitor ( e.g. , Diamox® Sequels® ) Memantine combine Nmethyl daspartate ( NMDA ) antagonists ( amantadine , ketamine , dextromethorphan ) Participants may receive investigational agent No current use illegal drug use prescription medication nonmedical reason</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>cancer survivor</keyword>
	<keyword>stage I non-small cell lung cancer</keyword>
	<keyword>stage II non-small cell lung cancer</keyword>
	<keyword>tobacco use disorder</keyword>
	<keyword>stage IA breast cancer</keyword>
	<keyword>stage IB breast cancer</keyword>
	<keyword>stage II breast cancer</keyword>
	<keyword>stage IIIA breast cancer</keyword>
	<keyword>stage IIIB breast cancer</keyword>
	<keyword>stage IIIC breast cancer</keyword>
	<keyword>stage I prostate cancer</keyword>
	<keyword>stage IIA prostate cancer</keyword>
	<keyword>stage IIB prostate cancer</keyword>
	<keyword>stage III prostate cancer</keyword>
	<keyword>stage I colon cancer</keyword>
	<keyword>stage IIA colon cancer</keyword>
	<keyword>stage IIB colon cancer</keyword>
	<keyword>stage IIC colon cancer</keyword>
	<keyword>stage IIIA colon cancer</keyword>
	<keyword>stage IIIB colon cancer</keyword>
	<keyword>stage IIIC colon cancer</keyword>
	<keyword>stage I rectal cancer</keyword>
	<keyword>stage IIA rectal cancer</keyword>
	<keyword>stage IIB rectal cancer</keyword>
	<keyword>stage IIC rectal cancer</keyword>
	<keyword>stage IIIA rectal cancer</keyword>
	<keyword>stage IIIB rectal cancer</keyword>
	<keyword>stage IIIC rectal cancer</keyword>
</DOC>